FDA makes it official, once again rejecting battered Correvio’s heart drug
Thirteen years after Correvio first tried — and failed — to gain an approval for the heart drug vernakalant, the FDA has handed them their latest CRL. It’s likely their last.
The agency spurned the little biotech — once called Cardiome — in the wake of a lopsided 11-2 vote against marketing approval. Subjected to a clinical hold at one stage, the atrial fibrillation drug has been under a dark safety cloud.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
